| Value | ₹3,990 Cr |
|---|---|
| Execution period | Expected to close in early 2027 |
BSE filing, NSE: AFFLE. Summary written from the filing by ALFA Finder's alert engine.
Affle 3I Ltd: key numbers
- Share price
- ₹1,341.80
- Market cap
- ₹19,308 Cr
- Revenue (annual)
- ₹2,709 Cr
- Net profit (annual)
- ₹454.9 Cr
- P/E (TTM)
- 40.4×Sector 23.5×
- Promoter holding
- 55.82%+0.91% QoQ
- FII holding
- 14.23%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Affle 3I Ltd
All →Affle 3I Results Update
Affle 3i reports Q2 FY2027 revenue of Rs 783.6 crore, up 21.2% y-o-y, with EBITDA up 24.2%. PAT rose 17.4% to Rs 129.8 crore.
Affle 3I Investor Presentation: Key Takeaways
Q2 FY27 revenue INR 7,836 mn (+21.2% YoY), EBITDA INR 1,814 mn (23.2% margin), PAT INR 1,298 mn (+17.4%). H1 revenue +20.8%, PAT +19.5%. CPCU conversions +18.2% YoY.
Affle 3I Q2 FY27 Results: Net Profit ₹129.8 Cr, Up 17.5% YoY
Affle 3I Ltd reported revenue from operations of ₹783.6 Cr (+21.2% YoY) and net profit of ₹129.8 Cr (+17.5% YoY) for Q2 FY27.
- Key figure
- Net profit ₹129.8 Cr · +17.5% YoY
Affle 3I Board Meeting Date
Affle 3i will hold a board meeting on 30 October 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended September 2026. This is a prior intimation, so the results are not yet approved.
Affle 3I Other Announcement
Affle 3i Ltd filed its quarterly shareholding pattern as of 19 October 2026. The filing reflects warrant-conversion share allotments to Affle Holdings.
Affle 3I Preferential Issue
Affle 3i converted 12,77,155 warrants into equity shares at ₹1,487 per share. The allotment raises approximately ₹189.91 Crore from a single investor.
- Value
- ₹189.9 Cr
Other acquisition announcements
All →Arvaya Healthcare Acquisition
Arvaya Healthcare completed the acquisition of 100% equity in Sushodha Institute of Gastroenterology Private Limited on 1 November 2026. The target is now a wholly-owned subsidiary, with no consideration amount disclosed.
Sai Parenterals Acquisition
Sai Parenterals will acquire the remaining 25% stake in its 75% subsidiary SP Analytics for cash, making it wholly owned. Related-party approval was taken at the 1 November 2026 board meeting, with completion by 31 December 2026.
- Execution
- 31-12-2026
R R Kabel Acquisition Worth ₹77 Cr
R R Kabel completed its acquisition of U M Cables' optical fibre business via slump sale for Rs.77 Crore. The transaction took effect from 31 October 2026.
- Value
- ₹77.00 Cr
R R Kabel Acquisition
R R Kabel completed its acquisition of U M Cables' business undertaking via slump sale, effective 31 October 2026. No consideration amount was disclosed in this intimation.
JSW Steel Acquisition
JSW Steel's scheme to amalgamate Piombino Steel became effective on 31 October 2026. Piombino now stands merged into JSW Steel under the NCLT-sanctioned scheme.
Sizemasters Technology Acquisition Worth ₹1.02 Cr
Sizemasters Technology agreed to acquire 60% of Ankita Innovations & Technologies for Rs 1.02 Crore in cash. The acquisition makes the target a subsidiary.
- Value
- ₹1.02 Cr